Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186947 | 0.87 | KMT2A (0.38) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL4191329 | 0.87 | MEN1 (0.45) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL4185104 | 0.83 | MEN1 (0.44) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL8296608 | 0.79 | MEN1 (0.51) | MEN1KMT2AKDM4CP2RX3NPC1 | |
| SCHEMBL4196206 | 0.79 | MEN1 (0.46) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL4193957 | 0.77 | KMT2A (0.39) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL5937239 | 0.77 | MEN1 (0.43) | MEN1KMT2AGCKKDM4C | |
| SCHEMBL4191448 | 0.77 | MEN1 (0.44) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL4192007 | 0.76 | NPC1 (0.41) | MEN1KMT2AGCKKDM4CP2RX3 | |
| SCHEMBL25833887 | 0.74 | MEN1 (0.38) | MEN1KMT2AGCKKDM4CP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | MEN1 532/4885KMT2A 2721/4885GCK 395/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | MEN1 1891/4885KMT2A 2009/4885GCK 746/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | MEN1 532/4885KMT2A 2721/4885GCK 395/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | MEN1 532/4885KMT2A 2721/4885GCK 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.